Antibiotics: Market Analysis & Business Opportunities
Antibiotics, also called antibacterials or antimicrobials, is a group of medicines used in the treatment of infections caused by germs—bacteria and certain parasites—by inhibiting the growth of microorganisms or killing them. Since the discovery of the antibiotic penicillin in 1920, various antibiotic compounds have been widely used to treat several bacterial infections. Increasing incidence of chronic and infectious diseases across the globe and efficacy of antibiotics to treat a wide spectrum of bacterial infections have led to the rapid evolution of the global antibiotic market. Based on geography, the report segments the global antibiotic markets into North America, Europe, Asia Pacific, and Rest of the World (ROW). Currently, Asia Pacific accounts for the leading share in the global antibiotic market. The region is likely to present exciting growth opportunities along the forecast period, driven by the prevalence of various infectious diseases, favorable regulatory reforms, and significant demand for generic medicines. A large number of players have been actively focusing on new drug development and clinical trials. Prominent biotechnology companies are entering into strategic alliances, which has helped them make considerable investments in drug discovery. Pharmaceutical companies are actively developing analogues of existing antibiotic classes based on innovative approaches to fight bacterial infections. Key players operating in the global antibiotic market include Pfizer Inc., Astellas Pharma, Inc, Roche, Novartis AG, Bristol-Myers Squibb Co., Bayer HealthCare AG, Abbott Laboratories, MiddleBrook Pharmaceuticals, Takeda Pharmaceutical Company, Ltd., Daiichi Sankyo Company, Ltd., GlaxoSmithKline Plc, Eli Lilly and Co., and Kyorin Pharmaceutical Co., Ltd. The antibiotics market was valued at USD 39.8 billion in 2015 and is expected to witness a CAGR of 4.0% over the forecast period. Increasing efforts are being witnessed toward the development of advanced products. According to the data published by the Pew Charitable Trust, in March 2016, about 37 promising molecules were being investigated within the U.S. market. Majority of these, are in phase II clinical trials and are anticipated to hit the market between 2018 - 2020. Furthermore, supportive government legislations, such as the Generating Antibiotics Incentives Now (GAIN) Act are expected to expedite the approval process. GAIN Act has provisions which facilitate development of therapy against antibiotic resistant pathogens.
Related Conference of Antibiotics: Market Analysis & Business Opportunities
10th International Congress on Trauma, Critical Care and Emergency Medicine
19th International Conference on Virology, Emerging Diseases & vaccines
7th International Conference on Antimicrobial and Antibacterial Agents
7th International Conference on Clinical Microbiology, Virology and Infectious Diseases
Antibiotics: Market Analysis & Business Opportunities Conference Speakers
Recommended Sessions
- Bacterial Genomics
- Advances in Antimicrobials, Vaccines and therapeutics
- Alternatives to Antibiotics
- Antibiotic Prophylaxis
- Antibiotic Regulatory Affairs
- Antibiotic Resistance
- Antibiotic sensitivity
- Antibiotics in Chronic Respiratory Diseases
- Antibiotics in Oncology
- Antibiotics in Our Food System
- Antibiotics: Market Analysis & Business Opportunities
- Anticancer Antibiotics
- Bacterial Biochemistry
- Bacterial Clinical Studies
- Bacterial Ecology
- Bacterial Identification Methods
- Bacterial infections
- Bacterial pathogenesis
- Bacterial physiology
- Bacterial Vaccine
- Bacterial vaginosis
- Bacteriology in Public Health
- Bacteriology of dental infections
- Clinical Bacteriology
- Clinical Trials of Antibiotics
- Emerging Infectious Diseases
- Food Poisoning Bacteria
- Medical Bacteriology and Immunology
- Medical Use of Antibiotics
- Microbial Pathogenesis
- MRSA
- Multi Pathogen Infections
- Naturopathy for Bacterial Infections
- Next-Generation Antibiotics
- Pharmacology of antibiotics
- Plant Bacteriology
- Toxicity of antibiotics
- Urinary Tract Infection (UTI)
Related Journals
Are you interested in
- Agriculture & Forest Microbiology - Microbiology 2024 (Switzerland)
- Agriculture Microbiology - Beneficial Microbes 2024 (Ireland)
- Antimicrobial Agents & Resistance - Microbiology 2024 (Switzerland)
- Applied and Environmental Science - Microbiology 2024 (Switzerland)
- Aquatic & Marine Microbiology - Microbiology 2024 (Switzerland)
- Bacteriology, Bacterial Pathogens & Associated diseases - Microbiology 2024 (Switzerland)
- Beneficial Microbes in the environment - Beneficial Microbes 2024 (Ireland)
- Biological Need of Trauma - TRAUMA 2024 (Netherlands)
- Blunt Trauma - TRAUMA 2024 (Netherlands)
- Cellular Microbiology & Systems Microbiology - Microbiology 2024 (Switzerland)
- Clinical and Neuro Virology - Virology-2024 (Canada)
- Clinical and Public Health Microbiology - Microbiology 2024 (Switzerland)
- Clinical Infections and Vaccines - Microbiology 2024 (Switzerland)
- Corona Virus - Virology-2024 (Canada)
- Critical Care in Trauma - TRAUMA 2024 (Netherlands)
- Delirium in Critical Care - TRAUMA 2024 (Netherlands)
- Ecology and Evolution of Microbe-Host Interactions - Beneficial Microbes 2024 (Ireland)
- Elderly Trauma and Critical Care - TRAUMA 2024 (Netherlands)
- Engineering Beneficial Microbes - Beneficial Microbes 2024 (Ireland)
- Environmental Microbiology (Soil Microbiology & Water Microbiology) - Microbiology 2024 (Switzerland)
- Evolution in Emergency Medicine Practices - TRAUMA 2024 (Netherlands)
- General Virology - Virology-2024 (Canada)
- HIV/AIDS and Sexually Transmitted Infections - Virology-2024 (Canada)
- Immunization and Immunotherapeutics - Virology-2024 (Canada)
- Immunobiotics - Beneficial Microbes 2024 (Ireland)
- Industrial Microbiology, Microbial Biotechnology and Future Bioindustries - Microbiology 2024 (Switzerland)
- Influenza and other Respiratory Diseases - Virology-2024 (Canada)
- Intensive Care in Trauma - TRAUMA 2024 (Netherlands)
- Marine Microbiology - Beneficial Microbes 2024 (Ireland)
- Medical Parasitology - Microbiology 2024 (Switzerland)
- Microbial Cytology, Microbial Physiology & Recombination DNA - Microbiology 2024 (Switzerland)
- Microbial Ecology and Evolution - Microbiology 2024 (Switzerland)
- Microbial Infections - Virology-2024 (Canada)
- Microbiome - Beneficial Microbes 2024 (Ireland)
- Molecular Microbiology - Microbiology 2024 (Switzerland)
- Mycology, Fungal Pathogens and Associated Diseases - Microbiology 2024 (Switzerland)
- New and Endogenous Retroviruses - Virology-2024 (Canada)
- New Technology in Trauma - TRAUMA 2024 (Netherlands)
- Novel Antiviral Therapies - Virology-2024 (Canada)
- Novel Vaccine Delivery Methods - Virology-2024 (Canada)
- Obstetric Trauma - TRAUMA 2024 (Netherlands)
- Paediatric Trauma - TRAUMA 2024 (Netherlands)
- Pathogenic Microbes in Immunology and Microbiology - Beneficial Microbes 2024 (Ireland)
- Pathogenic Microbes in Medicine and Dentistry - Beneficial Microbes 2024 (Ireland)
- Plant Pathology & Microbiology - Microbiology 2024 (Switzerland)
- Probiotics & Prebiotics - Beneficial Microbes 2024 (Ireland)
- Psychological Trauma - TRAUMA 2024 (Netherlands)
- Soil biological management - Beneficial Microbes 2024 (Ireland)
- Structural and Molecular virology - Virology-2024 (Canada)
- Transmission of Viruses - Virology-2024 (Canada)
- Transplant-Associated Viral Infections - Virology-2024 (Canada)
- Trauma & Critical Care Nursing - TRAUMA 2024 (Netherlands)
- Trauma Emergency Medicine - TRAUMA 2024 (Netherlands)
- Trauma in Nursing & Midwifery - TRAUMA 2024 (Netherlands)
- Trauma Therapy - TRAUMA 2024 (Netherlands)
- Trauma-An International Perspective - TRAUMA 2024 (Netherlands)
- Trauma-Mass Casualties Incidents - TRAUMA 2024 (Netherlands)
- Vaccines against Emerging Diseases (Ebola/Zika/Dengue/Chik) - Virology-2024 (Canada)
- Vaccines and the Microbiome - Virology-2024 (Canada)
- Veterinary Microbiology - Microbiology 2024 (Switzerland)
- Veterinary virology - Virology-2024 (Canada)
- Viral Genetics, Evolution and Dynamics - Virology-2024 (Canada)
- Viral Immunology and Immunopathology - Virology-2024 (Canada)
- Viral Oncology - Virology-2024 (Canada)
- Viral Pathogenesis - Virology-2024 (Canada)
- Virology, Viral Pathogens and Associated Diseases - Microbiology 2024 (Switzerland)